What is the recommended treatment for microangiopathic thrombocytopenic purpura?

Treatment of Microangiopathic Thrombocytopenic Purpura (TTP)

For immune-mediated TTP (iTTP), immediately initiate triple therapy with therapeutic plasma exchange (TPE), corticosteroids, and caplacizumab, followed by rituximab for immunosuppression 1. For congenital TTP (cTTP) in remission, use recombinant ADAMTS-13 as first-line prophylaxis 1.

Acute iTTP Management: The Triple Therapy Approach

The 2025 ISTH guidelines maintain the 2020 recommendations for iTTP, which have achieved remarkable mortality reduction to <5% when all components are used together 1. The treatment algorithm is straightforward:

Immediate Interventions (Start Before ADAMTS-13 Results)

• Therapeutic Plasma Exchange (TPE): Begin immediately upon clinical suspicion

  • TPE reduces mortality from 15.7% to 3.9% compared to no plasma exchange 2
  • Continue daily until platelet count normalizes and ADAMTS-13 activity improves
  • Provides ADAMTS-13 replacement while removing autoantibodies

• Caplacizumab: Start within 3 days of presentation for maximum benefit 1

  • Blocks VWF-platelet interaction, halting microthrombosis immediately
  • Achieves faster platelet normalization, fewer exacerbations, and reduced TPE requirements
  • Critical timing caveat: Delayed administration (>3 days) is less effective because irreversible organ damage has already occurred 1
  • Continue for 30 days after stopping TPE, or longer if ADAMTS-13 remains <10% 1
  • Bleeding risk: 11% vs 1% in placebo, but events resolve without major intervention 3

• High-dose Corticosteroids:

  • Prednisone 1 mg/kg/day orally OR methylprednisolone 125 mg IV 2-4 times daily 1
  • Continue until platelet recovery sustained for 5-7 days, then taper over 3 weeks

Early Immunosuppression

• Rituximab: Initiate early in the acute phase
  • Standard dosing: 375 mg/m² weekly × 4 doses
  • Suppresses anti-ADAMTS-13 autoantibody production
  • Combined with caplacizumab, TPE, and steroids: mortality drops to 2.2% vs 12.2% historical controls 2

Congenital TTP (cTTP) Management

The 2025 guidelines issued new strong recommendations for cTTP prophylaxis 1:

For Patients in Remission

• First-line: Recombinant ADAMTS-13 (strong recommendation, moderate certainty evidence)

  • Provides optimal balance of benefits and risks
  • Fewer adverse events than plasma (no allergic reactions, anaphylaxis, volume overload, or infections) 1
  • Currently approved in USA, Europe, and Japan

• Second-line: Fresh Frozen Plasma (FFP) if recombinant ADAMTS-13 unavailable

  • Regular infusion at predefined dosage/interval prevents acute TTP events 1
  • Requires 30-40 mL/kg/week during pregnancy with close monitoring 1

Special Consideration: Pregnancy in cTTP

• Extremely high risk: 10% maternal mortality, >50% fetal loss without prophylaxis 1
• Start prophylaxis early in pregnancy
• Recombinant ADAMTS-13 is highly efficacious and safe (case reports show live births, no maternal mortality) 1
• If unavailable, use higher-dose FFP (30-40 mL/kg/week) with intensive monitoring

Critical Diagnostic Points

Before initiating treatment, draw blood for ADAMTS-13 activity and inhibitor levels. Do not delay treatment waiting for results 3. Use clinical scoring:

• PLASMIC score or French score to assess pre-test probability
• ADAMTS-13 activity <10% with positive inhibitor confirms iTTP 1
• Absence of inhibitor doesn't rule out iTTP initially (may be undetectable due to antibody-ADAMTS-13 complexes) 1

Common Pitfalls to Avoid

1. Delaying caplacizumab: Starting >3 days after presentation significantly reduces efficacy because microvascular damage is already established 1

2. Withholding antiplatelet agents inappropriately: Generally avoid in acute phase when platelets <50 × 10⁹/L, but do not withhold in setting of macrothrombotic complications (stroke, MI) - consult multidisciplinary team 1

3. Platelet transfusions: Contraindicated unless life-threatening bleeding - may worsen thrombosis

4. Premature steroid taper: Wait until platelet recovery sustained 5-7 days, then taper over 3 weeks minimum 1

5. Stopping caplacizumab too early: Continue minimum 30 days post-TPE; extend if ADAMTS-13 <10% to prevent relapse 1

Refractory Cases

For patients unresponsive to standard therapy, consider:

• Azathioprine for persistent autoantibody production 1
• Eculizumab (anti-C5) in very selected refractory cases - use with caution 1
• Avoid: Intravenous immunoglobulin (adverse reactions mimic TTP manifestations) 1

Long-Term Monitoring

iTTP is now recognized as a chronic disorder, not just an acute episode 4. Survivors face heightened risks of stroke, cardiovascular disease, neurocognitive impairment, and kidney disease even during remission. Regular ADAMTS-13 monitoring and clinical follow-up are essential for detecting relapse risk and managing long-term sequelae.